Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase IIa Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 (a LOXL2 Inhibitor) in Participants With Myelofibrosis (MF)

NCT04679870 is registered in ClinicalTrials.gov with Galecto Biotech AB as lead sponsor.

NCT NCT04679870
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04679870 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase IIa Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 (a LOXL2 Inhibitor) in Participants With Myelofibrosis (MF)
Lead sponsor
Galecto Biotech AB
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 9, 2021
Completion date
June 30, 2026
Enrollment
21 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis